Font Size Smaller Font Size
Larger Font Size
Latest Press Releases
-
June 3, 2018
Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of liso-cel (JCAR017) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO
-
June 3, 2018
Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R²) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018
-
June 1, 2018
Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
-
June 1, 2018
Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma
-
May 31, 2018
Celgene Corporation Announces Hiring of David V. Elkins as Executive Vice President, Chief Financial Officer and Appointment of Peter N. Kellogg to Executive Vice President, Chief Corporate Strategy Officer
No results found.